Mon, Jul 28, 2014, 4:33 AM EDT - U.S. Markets open in 4 hrs 57 mins

Recent

% | $
Click the to save as a favorite.

Astex Pharmaceuticals, Inc. Message Board

  • ainke ainke Mar 15, 2007 8:29 AM Flag

    32 million vs 27 million

    March 14 (Reuters) - Biotechnology company Supergen Inc. (SUPG.O: Quote, Profile , Research) said it expects loss from operations in 2007 of $500,000 to $1 million and revenue of about $32 million.

    In a conference call, the company said it sees research and development expenses of between $21 million and $22.5 million in 2007. Supergen said it sees non-cash stock option expense of $3.5 million to $4 million in the year.

    Analysts on average expect revenue of $27.9 million, according to Reuters Estimates. (Reporting by Neha Pathania in Bangalore)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 2007 Numbers should be higher:

      11.2M Deferred gain on sale of Nipent
      10.3M Acceleration clause
      3.25M Nipent EU sale
      17.1M Dacogen Royalities -Low end
      3.5M Interest Income

      45.35M Revenues 2007

      We will take a little hit this morning, but institutions will swallow it up. We'll end up around 5.25 today. Like one poster stated it nicely...announcements coming. Mgi stated today that the MDS markets growing 35% per year and Dacogen has better data, better ease of use. The other key point presented today and confirms what Dr. Manuso hinted at, trials are on going in U.S and EU on AML, this leads me to believe that JNJ will file for both MDS and AML around the same time. This makes sense to get the best labeling posibile in EU, takes a little longer but comes out of the blocks fast. MGI has Dacogen projections Greater than 250M...and I believe we see 300M projections by end of the year. Spinout company will be funded with outside money and not by SUPG, this is very important, shareholders will get a piece of new company for nothing. Here's a question for longs, was Orathecin a capsule form drug? They have change the web page and listed it as a phase II drug and now states it's in a capsule form. I wasn't around back then so I'm not sure of how it was administered. I'm probably looking for someone's opinion outside Rory, since after his post I would have to do to much work correcting it. Sorry Rory, just a fact of life. Long term we will move higher.

 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSEFri, Jul 25, 2014 4:01 PM EDT
Sohu.com Inc.
NasdaqGSFri, Jul 25, 2014 3:59 PM EDT